Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS(R) T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. The company's lead product candidate includes EB103 and EB104. Estrella Immunopharma Inc., formerly known as TradeUP Acquisition Corp., is based in NEW YORK.
Info & Links
CEO
Cheng Liu
Headquarters
5858 Horton Street, Suite 370 Emeryville, CA 94608, UNITED STATES
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.